The drug executive President Donald Trump has picked to lead the Department Health and Human Services isn’t likely to shy away from the topic of sky-high medication prices -- but it may be insurers and drug plans that feel the heat as much as his former industry.
Trump’s pick, former Eli Lilly & Co. executive Alex Azar has talked about drug prices during interviews, speeches and panel appearances before leaving Lilly in January and in the months after. His remarks have paralleled a common industry argument, that it’s other parts of the pharmaceutical supply chain that bear a large share of the blame for U.S. outrage over drug costs.
“Why did things erupt? They erupted because we have seen a complete and fundamental restructuring of health insurance in the United States over the last three to five years,” Azar said at a conference in May hosted by a medical software company.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.